Ambrosia Bio raises $100M for oral GLP-1 trial
Ambrosia Biosciences has closed an $100 million Series B round to fund clinical trials of its oral small molecule GLP-1 weight loss drug candidate.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Already have a paid subscription?



